ADVERTISEMENT
Navigating the Cost, Challenges, and Complexities of Ketamine for Depression Treatment
Andrew Penn, MS, PMHNP, explores ketamine as a rapidly acting antidepressant, unraveling its effectiveness and limitations. Penn discusses the evolving questions around redosing, financial implications, and pragmatic considerations for clinicians in managing patients with these treatments.
For more depression clinical pearls, rapid refreshers, and perspectives, visit the Depression and MDD Learning Library.
Andrew Penn, MS, PMHNP, has practiced as a psychiatric/mental health nurse practitioner, treating veterans and training residents at the San Francisco Veterans Administration Hospital. As a researcher, he collaborates on psychedelics studies of psilocybin and MDMA in the Translational Psychedelics Research (TrPR) lab at UCSF, serving as Co-PI on a phase 2 study of psilocybin for depression and is currently working on a study using psilocybin to treat depression in patients with Parkinson's disease. He is a cofounder of the Organization of Psychedelic and Entheogenic Nurses, he has published on psychedelics in the American Journal of Nursing, Frontiers in Psychiatry, and The Journal of Humanistic Psychotherapy. Penn has also lectured at SXSW, Aspen Health Ideas Festival, the Singapore Ministry of Health, TEDx, and Oxford University.
Transcript coming soon.
Nurse Practitioners are at the heart of today's health care system. With the increased need for mental health and psychiatric services, you need in-depth education tailored to your practice in order to provide the best possible care to all patients. The Psych Congress NP Institute event is an essential educational experience, crafted by the world-class leaders of Psych Congress.
Discover this newly available offering that will take a deep dive into everything you need to know about psychopharmacology but have been afraid to ask, including basic psychopharmacology principles and terminology on treatment, disease states, and medication types.
